8-K current report · filed Oct 14, 2026

Aquestive Therapeutics, Inc. (AQST) 8-K Current Report: October 14, 2026

Item 1.01AQST overview

Short answer

Aquestive Therapeutics, Inc. (AQST) filed an 8-K current report with the SEC on October 14, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Exclusive U.S. commercialization rights granted to Eton for LIBERVANT, subject to FDA approvals.

Aquestive Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Exclusive U.S. commercialization rights granted to Eton for LIBERVANT, subject to FDA approvals
  • $10.0M upfront fee received, with up to $47.5M in regulatory and commercial milestones
  • Mid-teens royalties on annual U.S. net sales, creating ongoing revenue participation
  • Aquestive remains exclusive manufacturer and supplier under a 20-year initial supply term
  • Commercial launch depends on full FDA approval, including potential expansion to ages 2–5 and 6–11

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Aquestive Therapeutics, Inc. 8-K filings

Get the next AQST 8-K as it lands

Follow AQST for push alerts, or ask the research agent what this filing means.